WST · West Pharmaceutical Services Inc
Price
Snapshot
50 fields · last close| Market Cap | $23.90B |
| P/E | 49.78 |
| Float | 69.91M |
| Beta | 1.15 |
| Volatility | 28.7% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 82.7 |
| Price | 385.13 |
| Change | +0.29% |
| Prev Close | 384.02 |
| Open | 382.74 |
| Day Low | 380.28 |
| Day High | 386.26 |
| Avg Vol | 0 |
| Avg $ Vol | $179.5M |
| 52W High | 386.26 |
| 52W Low | 223.83 |
| 52W Pos | 99.3% |
| From High | −0.29% |
| From Low | +72.06% |
| Max DD 1Y | −24.83% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.64% |
| SMA 50 | +7.54% |
| SMA 200 | +25.33% |
| RSI (14) | 65.6 |
| Vol 30D | 22.4% |
| Vol 90D | 23.9% |
| 1Y Range | 224–386 |
| Daily bars | 536 |
| Perf Week | +4.92% |
| Perf Month | +4.75% |
| Perf Quarter | +9.00% |
| Perf Half Y | +40.29% |
| Perf Year | +46.04% |
| Perf YTD | +39.34% |
| Prev Day | +0.29% |
| Clavix | A- |
| Debt / Eq | 0.06 |
| Curr Ratio | 3.02 |
| Int Cover | 128.5× |
| FCF Margin | 15.2% |
| Rev Growth | +6.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 1 / 19 |
What WST does
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Clavix risk grade
regraded every trading dayWST grades A-, 82.7 of 100. Steadiest on Sector Resilience (74), most exposed on Macro Resilience (64, mixed). 3 of the 3 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 1 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| WST | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.15 | 1.18 |
| Volatilityannualized | 28.7% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −24.8% | — |
| Typical daily movemedian absolute daily change | 1.12% | — |
| Days beyond ±3%of the last 252 sessions | 23 (9%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| WST | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.15 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| WST | |
|---|---|
| 1 week | +4.9% |
| 1 month | +4.8% |
| Year to date | +39.3% |
| 1 year | +46.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| WST | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 22 Jul |
| Average score0 most bearish, 100 most bullish | 64 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 1 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| WST | |
|---|---|
| Revenue growthyear over year | +6.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openJoseph M. Terranova, senior managing director at Virtus Investment Partners, said on CNBC's 'Halftime Report Final Trades' that he likes West Pharmaceutical Services (WST). The article provides no further detail on his reasoning.
An analyst keeps a buy rating on West Pharmaceutical Services, pointing to double-digit growth from GLP-1 injectable drugs, ongoing HVP product upgrades, and a multiyear regulatory opportunity tied to EU Annex 1 sterile-manufacturing rules, of which only about $1 billion of a $6 billion component opportunity has been captured so far.
West Pharmaceutical Services is phasing out a product line at its Scottsdale facility by the end of September, cutting 98 jobs and shifting the related manufacturing work to other Becton, Dickinson and Co. locations. The company is pushing into higher-value products and making sterility upgrades required by Annex 1 regulations, but is dealing with cyber incident disruptions in its West Vantage segment and cost pressures from tariffs and commodities.
West Pharmaceutical Services is dealing with mixed signals as investors weigh long-term growth drivers against fresh headwinds from a cyber incident, rising costs, and the shutdown of its Scottsdale product line. The stock is up about 10% over the past 90 days and roughly 31% year to date, while the one-year total shareholder return of about 43% contrasts with a slightly negative three-year total return.
An opinion piece recommends buying West Pharmaceutical, citing its biologics business, work tied to new EU sterile-manufacturing rules (Annex 1), and growth in delivery-device products, while acknowledging unspecified near-term challenges.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MTD | Mettler-toledo International Inc | B+ | $32.51B | 35.89 | 1.19 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.26B | 35.12 | 1.11 | Compare |
| RVTY | Revvity Inc | B | $17.03B | 71.70 | 1.09 | Compare |
| ILMN | Illumina Inc | B- | $39.64B | 48.05 | 1.43 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.33B | — | 1.37 | Compare |
| WAT | Waters Corp | B+ | $43.78B | 263.53 | 1.16 | Compare |
| IQV | IQVIA Holdings Inc | B | $43.93B | 31.95 | 1.18 | Compare |
| A | Agilent Technologies Inc | B | $48.77B | 33.86 | 1.25 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.